Trials / Completed
CompletedNCT00955604
Azilect + Antidepressant Chart Review
Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Group R+AD Rasagiline + Antidepressant | Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days |
| DRUG | Group R Rasagiline | At least 2 months of rasagiline |
| DRUG | Group AD Anti-PD + Antidepressant | An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication. |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-03-01
- Completion
- 2010-06-01
- First posted
- 2009-08-10
- Last updated
- 2017-02-06
Source: ClinicalTrials.gov record NCT00955604. Inclusion in this directory is not an endorsement.